

Tim Friede

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/166252/publications.pdf>

Version: 2024-02-01

304
papers

10,448
citations

36271

51
h-index

51562

86
g-index

330
all docs

330
docs citations

330
times ranked

12810
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. <i>Neurology</i> , 2005, 65, 812-819.	1.5	583
2	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet</i> , The, 2020, 396, 1895-1904.	6.3	425
3	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. <i>Journal of Clinical Oncology</i> , 2019, 37, 3212-3222.	0.8	333
4	Warwick-Edinburgh Mental Well-being Scale (WEMWBS): Validated for teenage school students in England and Scotland. A mixed methods assessment. <i>BMC Public Health</i> , 2011, 11, 487.	1.2	312
5	Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. <i>Kidney International</i> , 2012, 81, 494-501.	2.6	275
6	Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. <i>European Heart Journal</i> , 2018, 39, 1065-1074.	1.0	262
7	Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. <i>BMC Medical Research Methodology</i> , 2015, 15, 99.	1.4	181
8	Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. <i>Lancet Psychiatry</i> , the, 2017, 4, 725-732.	3.7	174
9	Effect and Feasibility of Controlled Rewarming After Moderate Hypothermia in Stroke Patients With Malignant Infarction of the Middle Cerebral Artery. <i>Stroke</i> , 2001, 32, 2833-2835.	1.0	168
10	Sample Size Recalculation in Internal Pilot Study Designs: A Review. <i>Biometrical Journal</i> , 2006, 48, 537-555.	0.6	153
11	Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. <i>Neurology</i> , 2013, 81, 1226-1234.	1.5	153
12	Monitoring of 30 marker candidates in early Parkinson disease as progression markers. <i>Neurology</i> , 2016, 87, 168-177.	1.5	133
13	Methods for evidence synthesis in the case of very few studies. <i>Research Synthesis Methods</i> , 2018, 9, 382-392.	4.2	132
14	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2022, 8, e215445.	3.4	127
15	Meta-analysis of few small studies in orphan diseases. <i>Research Synthesis Methods</i> , 2017, 8, 79-91.	4.2	126
16	Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. <i>American Journal of Transplantation</i> , 2019, 19, 3087-3099.	2.6	125
17	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	0.9	123
18	Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). <i>Movement Disorders</i> , 2019, 34, 67-77.	2.2	120

#	ARTICLE	IF	CITATIONS
19	Re-calculating the sample size in internal pilot study designs with control of the type I error rate. , 2000, 19, 901-911.		108
20	Simple procedures for blinded sample size adjustment that do not affect the type I error rate. <i>Statistics in Medicine</i> , 2003, 22, 3571-3581.	0.8	108
21	Telephone peer-delivered intervention for diabetes motivation and support: The telecare exploratory RCT. <i>Patient Education and Counseling</i> , 2009, 75, 91-98.	1.0	99
22	A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alportâ€™s syndrome. <i>Kidney International</i> , 2020, 97, 1275-1286.	2.6	94
23	Pro-Active Call Center Treatment Support (PACCTS) to Improve Glucose Control in Type 2 Diabetes: A randomized controlled trial. <i>Diabetes Care</i> , 2005, 28, 278-282.	4.3	93
24	Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 99-119.	0.4	93
25	A groupâ€™s sequential design for clinical trials with treatment selection. <i>Statistics in Medicine</i> , 2008, 27, 6209-6227.	0.8	90
26	Reclassifying Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1586-1595.	2.5	87
27	Results of medial patellofemoral ligament reconstruction compared with trochleoplasty plus individual extensor apparatus balancing in patellar instability caused by severe trochlear dysplasia: a systematic review and meta-analysis. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2017, 25, 3869-3877.	2.3	86
28	Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1641-1652.	1.4	86
29	Metaâ€™analysis of two studies in the presence of heterogeneity with applications in rare diseases. <i>Biometrical Journal</i> , 2017, 59, 658-671.	0.6	84
30	Cross cultural evaluation of the Warwick-Edinburgh mental well-being scale (WEMWBS) -a mixed methods study. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 27.	1.0	83
31	Clinical presentation of pediatric multiple sclerosis before puberty. <i>European Journal of Neurology</i> , 2014, 21, 441-446.	1.7	83
32	A comparison of methods for adaptive sample size adjustment. <i>Statistics in Medicine</i> , 2001, 20, 3861-3873.	0.8	81
33	A conditional error function approach for subgroup selection in adaptive clinical trials. <i>Statistics in Medicine</i> , 2012, 31, 4309-4320.	0.8	80
34	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€™Age Paradigm. <i>Annals of Neurology</i> , 2020, 88, 93-105.	2.8	79
35	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. <i>European Heart Journal</i> , 2020, 41, 3437-3447.	1.0	78
36	Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies. <i>BMC Medical Research Methodology</i> , 2019, 19, 16.	1.4	77

#	ARTICLE	IF	CITATIONS
37	Pilot of "Families for Health": community-based family intervention for obesity. Archives of Disease in Childhood, 2008, 93, 921-928.	1.0	76
38	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure, 2020, 7, 3298-3309.	1.4	76
39	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	1.0	71
40	Doxycycline in early CJD: a double-blinded randomised phase II and observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 119-125.	0.9	70
41	Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 970-976.	0.9	69
42	Exercise Stress Real-Time Cardiac Magnetic Resonance Imaging for Noninvasive Characterization of Heart Failure With Preserved Ejection Fraction. Circulation, 2021, 143, 1484-1498.	1.6	69
43	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	1.0	65
44	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, 2016, 37, 747-754.	1.0	62
45	Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients. ISRN Pediatrics, 2012, 2012, 1-6.	1.2	60
46	Evaluation of dysphagia by novel real-time MRI. Neurology, 2016, 87, 2132-2138.	1.5	60
47	Impact of COVID-19 outbreak on regional STEMI care in Germany. Clinical Research in Cardiology, 2020, 109, 1511-1521.	1.5	60
48	Multiple sclerosis registries in Europe – results of a systematic survey. Multiple Sclerosis Journal, 2014, 20, 1523-1532.	1.4	58
49	Sources of Information and Behavioral Patterns in Online Health Forums: Qualitative Study. Journal of Medical Internet Research, 2014, 16, e10.	2.1	58
50	On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation. Statistics in Medicine, 2002, 21, 165-176.	0.8	57
51	Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine, 2011, 30, 1528-1540.	0.8	57
52	Random-effects meta-analysis of few studies involving rare events. Research Synthesis Methods, 2020, 11, 74-90.	4.2	57
53	Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection. Journal of Biopharmaceutical Statistics, 2014, 24, 168-187.	0.4	55
54	On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis. Research Synthesis Methods, 2021, 12, 448-474.	4.2	55

#	ARTICLE	IF	CITATIONS
55	Differences in the Responses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 428.	4.5	54
56	Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries. <i>Europace</i> , 2018, 20, 963-970.	0.7	54
57	ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 293.	1.1	54
58	Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1211-1217.	1.4	53
59	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	3.1	53
60	A Comparison of Methods for Adaptive Treatment Selection. <i>Biometrical Journal</i> , 2008, 50, 767-781.	0.6	51
61	Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis. <i>Statistics in Medicine</i> , 2010, 29, 1145-1156.	0.8	51
62	Adhesion Maturation of Neutrophils on Nanoscopically Presented Platelet Glycoprotein Ib/α. <i>ACS Nano</i> , 2013, 7, 9984-9996.	7.3	51
63	Anticholinergics for urinary symptoms in multiple sclerosis. , 2009, , CD004193.		50
64	Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. <i>JAMA Network Open</i> , 2020, 3, e2012469.	2.8	50
65	Planning and analysis of three-arm non-inferiority trials with binary endpoints. <i>Statistics in Medicine</i> , 2007, 26, 253-273.	0.8	49
66	Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. <i>Lancet, The</i> , 2019, 394, 1344-1351.	6.3	49
67	A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 81-88.	1.4	46
68	Assessment of statistical significance and clinical relevance. <i>Statistics in Medicine</i> , 2013, 32, 1707-1719.	0.8	44
69	Sample size recalculation for binary data in internal pilot study designs. <i>Pharmaceutical Statistics</i> , 2004, 3, 269-279.	0.7	42
70	Systematic Review of Randomized Controlled Trials of Clinical Prediction Rules for Physical Therapy in Low Back Pain. <i>Spine</i> , 2013, 38, 762-769.	1.0	42
71	Blinded sample size reassessment in non-inferiority and equivalence trials. <i>Statistics in Medicine</i> , 2003, 22, 995-1007.	0.8	41
72	Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials. <i>Methods of Information in Medicine</i> , 2010, 49, 618-624.	0.7	41

#	ARTICLE	IF	CITATIONS
73	Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. <i>Biometrical Journal</i> , 2017, 59, 804-825.	0.6	41
74	Validation and Reliability of the Neuropathic Pain Scale (NPS) in Multiple Sclerosis. <i>Clinical Journal of Pain</i> , 2007, 23, 473-481.	0.8	40
75	Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw095.	0.4	40
76	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 483-497.	0.6	40
77	Calcineurin Inhibitor Sparing With Mycophenolate Mofetil in Liver Transplantation: A Systematic Review of Randomized Controlled Trials. <i>American Journal of Transplantation</i> , 2012, 12, 2601-2607.	2.6	39
78	On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. <i>Pharmaceutical Statistics</i> , 2019, 18, 166-183.	0.7	38
79	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 107-109.	0.9	38
80	Therapeutic Apheresis in Pediatric Patients with Acute CNS Inflammatory Demyelinating Disease. <i>Blood Purification</i> , 2013, 36, 92-97.	0.9	35
81	Severe heart failure and the need for mechanical circulatory support and heart transplantation in pediatric patients with myocarditis: Results from the prospective multicenter registry MYKKE. <i>Pediatric Transplantation</i> , 2019, 23, e13548.	0.5	35
82	Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies. <i>Pediatric Transplantation</i> , 2014, 18, 839-850.	0.5	33
83	Applications of artificial intelligence/machine learning approaches in cardiovascular medicine: a systematic review with recommendations. <i>European Heart Journal Digital Health</i> , 2021, 2, 424-436.	0.7	33
84	Reporting FDR analogous confidence intervals for the log fold change of differentially expressed genes. <i>BMC Bioinformatics</i> , 2011, 12, 288.	1.2	32
85	Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 89-98.	1.2	32
86	Back schools for the treatment of chronic low back pain: possibility of benefit but no convincing evidence after 47 years of research—systematic review and meta-analysis. <i>Pain</i> , 2016, 157, 2160-2172.	2.0	31
87	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 461-477.	0.6	31
88	Automated electronic reminders to facilitate primary cardiovascular disease prevention: randomised controlled trial. <i>British Journal of General Practice</i> , 2010, 60, e137-e143.	0.7	30
89	Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators. <i>Europace</i> , 2016, 18, 1194-1202.	0.7	30
90	Toward evidence-based diagnosis of myocarditis in children and adolescents: Rationale, design, and first baseline data of MYKKE, a multicenter registry and study platform. <i>American Heart Journal</i> , 2017, 187, 133-144.	1.2	30

#	ARTICLE	IF	CITATIONS
91	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 186.	1.2	30
92	Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. <i>Scientific Reports</i> , 2021, 11, 13340.	1.6	30
93	Development of oral immunomodulatory agents in the management of multiple sclerosis. <i>Drug Design, Development and Therapy</i> , 2011, 5, 255.	2.0	29
94	Dynamically borrowing strength from another study through shrinkage estimation. <i>Statistical Methods in Medical Research</i> , 2020, 29, 293-308.	0.7	29
95	A Bootstrap Procedure for Adaptive Selection of the Test Statistic in Flexible Two-Stage Designs This paper is based on a presentation given at the Workshop "Frontiers in Adaptive Designs", 17.-18. 5. 2001, Vienna/Austria.. <i>Biometrical Journal</i> , 2002, 44, 641.	0.6	28
96	Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1580-1586.	1.4	28
97	Power and sample size determination when assessing the clinical relevance of trial results by "responder analyses". <i>Statistics in Medicine</i> , 2004, 23, 3287-3305.	0.8	27
98	Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis. <i>Pharmaceutical Statistics</i> , 2011, 10, 8-13.	0.7	27
99	Blinded sample size estimation in superiority and noninferiority trials: bias versus variance in variance estimation. <i>Pharmaceutical Statistics</i> , 2013, 12, 141-146.	0.7	27
100	Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. <i>BMC Family Practice</i> , 2014, 15, 45.	2.9	27
101	Is there a role for statistics in artificial intelligence?. <i>Advances in Data Analysis and Classification</i> , 2022, 16, 823-846.	0.9	27
102	Primum non nocere: shared informed decision making in low back pain " a pilot cluster randomised trial. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 282.	0.8	26
103	A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 170-189.	0.4	26
104	Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) " a double-blind, randomized, controlled comparative effectiveness trial. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 203.	3.7	26
105	Gender Differences in Appropriate Shocks and Mortality among Patients with Primary Prophylactic Implantable Cardioverter-Defibrillators: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0162756.	1.1	26
106	Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1290-1296.	1.4	25
107	EFSPi/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets " a primer for academic researchers. <i>BMC Medical Research Methodology</i> , 2016, 16, 73.	1.4	25
108	Discrete Approximation of a Mixture Distribution via Restricted Divergence. <i>Journal of Computational and Graphical Statistics</i> , 2017, 26, 217-222.	0.9	25

#	ARTICLE	IF	CITATIONS
109	On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation by T. Friede and M. Kieser, <i>Statistics in Medicine</i> 2002;21:165–176. <i>Statistics in Medicine</i> , 2005, 24, 147-154.	0.8	23
110	Exploring changes in treatment effects across design stages in adaptive trials. <i>Pharmaceutical Statistics</i> , 2009, 8, 62-72.	0.7	23
111	A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 330-338.	0.9	23
112	A design-by-treatment interaction model for network meta-analysis and meta-regression with integrated nested Laplace approximations. <i>Research Synthesis Methods</i> , 2018, 9, 179-194.	4.2	23
113	Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. <i>The Cochrane Library</i> , 2018, 2018, CD011005.	1.5	22
114	Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 24-30.	1.0	21
115	Model averaging for robust extrapolation in evidence synthesis. <i>Statistics in Medicine</i> , 2019, 38, 674-694.	0.8	21
116	Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R. <i>Biometrical Journal</i> , 2020, 62, 1264-1283.	0.6	21
117	Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. <i>European Journal of Heart Failure</i> , 2021, 23, 1891-1902.	2.9	21
118	Blinded Sample Size Reestimation in Multiarmed Clinical Trials. <i>Drug Information Journal</i> , 2000, 34, 455-460.	0.5	20
119	Economic Analysis of a Telemedicine Intervention to Improve Glycemic Control in Patients with Diabetes Mellitus. <i>Disease Management and Health Outcomes</i> , 2006, 14, 377-385.	0.3	20
120	Systematic review of sonographic chronic cerebrospinal venous insufficiency findings in multiple sclerosis. <i>Phlebology</i> , 2011, 26, 319-325.	0.6	19
121	Blinded sample size re-estimation in crossover bioequivalence trials. <i>Pharmaceutical Statistics</i> , 2014, 13, 157-162.	0.7	19
122	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. <i>European Journal of Heart Failure</i> , 2017, 19, 449-456.	2.9	19
123	Differential multivariable risk prediction of appropriate shock versus competing mortality - A prospective cohort study to estimate benefits from ICD therapy. <i>International Journal of Cardiology</i> , 2018, 272, 102-107.	0.8	19
124	Exercise training in patients with a left ventricular assist device (ExVAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1152-1159.	2.9	19
125	Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. <i>Europace</i> , 2021, 23, 887-897.	0.7	19
126	Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29. <i>PLoS Medicine</i> , 2017, 14, e1002346.	3.9	19

#	ARTICLE	IF	CITATIONS
127	Blinded Sample Size Reestimation in Non-Inferiority Trials with Binary Endpoints. <i>Biometrical Journal</i> , 2007, 49, 903-916.	0.6	18
128	Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 905-915.	1.0	18
129	Educating Orally Anticoagulated Patients in Drug Safety. <i>Deutsches Arzteblatt International</i> , 2014, 111, 607-14.	0.6	18
130	Memorandum "Open Metadata". <i>Methods of Information in Medicine</i> , 2015, 54, 376-378.	0.7	18
131	Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , 2017, 77, 885-910.	4.9	18
132	Insights into permanent pacemaker implantation following TAVR in a real-world cohort. <i>PLoS ONE</i> , 2018, 13, e0204503.	1.1	18
133	Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation. <i>ESC Heart Failure</i> , 2019, 6, 182-193.	1.4	18
134	Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2020, 10, e040119.	0.8	18
135	A note on change point estimation in dose-response trials. <i>Computational Statistics and Data Analysis</i> , 2001, 37, 219-232.	0.7	17
136	Data-driven treatment selection for seamless phase II/III trials incorporating early outcome data. <i>Pharmaceutical Statistics</i> , 2014, 13, 238-246.	0.7	17
137	Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis – an observational study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 587-593.	1.7	17
138	Biometrical Journal and Reproducible Research. <i>Biometrical Journal</i> , 2009, 51, 553-555.	0.6	16
139	Practice nurse-based, individual and video-assisted patient education in oral anticoagulation - Protocol of a cluster-randomized controlled trial. <i>BMC Family Practice</i> , 2011, 12, 17.	2.9	16
140	Prediction of Appropriate Shocks Using 24-Hour Holter Variables and T-Wave Alternans After First Implantable Cardioverter-Defibrillator Implantation in Patients With Ischemic or Nonischemic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 86-94.	0.7	16
141	Survival analysis for Adverse events with Varying follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study. <i>Biometrical Journal</i> , 2021, 63, 650-670.	0.6	16
142	The impact of smoking cessation on multiple sclerosis disease progression. <i>Brain</i> , 2022, 145, 1368-1378.	3.7	16
143	Optimal choice of the number of treatments to be included in a clinical trial. <i>Statistics in Medicine</i> , 2009, 28, 1321-1338.	0.8	15
144	Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype. <i>Europace</i> , 2012, 14, 416-422.	0.7	15

#	ARTICLE	IF	CITATIONS
145	An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. <i>Computational Statistics and Data Analysis</i> , 2012, 56, 1150-1160.	0.7	15
146	Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care. <i>BMC Family Practice</i> , 2014, 15, 104.	2.9	15
147	Sample size calculation in multi-centre clinical trials. <i>BMC Medical Research Methodology</i> , 2018, 18, 156.	1.4	15
148	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	2.9	15
149	Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data. <i>Statistics in Medicine</i> , 2013, 32, 3055-3066.	0.8	14
150	Design and analysis of three-arm trials with negative binomially distributed endpoints. <i>Statistics in Medicine</i> , 2016, 35, 505-521.	0.8	14
151	Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials. <i>Computational Statistics and Data Analysis</i> , 2017, 113, 100-110.	0.7	14
152	Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1879-1892.	0.7	14
153	A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations. <i>Pharmaceutical Statistics</i> , 2019, 18, 600-626.	0.7	14
154	A systematic review and meta-analysis of published cases reveals the natural disease history in multiple sulfatase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1288-1297.	1.7	14
155	Long-term effects of a standardized feedback-driven quality improvement program for timely reperfusion therapy in regional STEMI care networks. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 397-405.	0.4	14
156	Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1441-1447.	2.8	14
157	On the role of data, statistics and decisions in a pandemic. <i>AStA Advances in Statistical Analysis</i> , 2022, 106, 349-382.	0.4	14
158	Blinded Continuous Monitoring of Nuisance Parameters in Clinical Trials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2012, 61, 601-618.	0.5	13
159	Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2015, 10, e0137052.	1.1	13
160	Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial. <i>Statistics in Medicine</i> , 2015, 34, 3104-3115.	0.8	13
161	A studentized permutation test for three-arm trials in the "gold standard" design. <i>Statistics in Medicine</i> , 2017, 36, 883-898.	0.8	13
162	Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies. <i>Statistical Methods in Medical Research</i> , 2018, 27, 3286-3303.	0.7	13

#	ARTICLE	IF	CITATIONS
163	Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis. <i>Pharmaceutical Statistics</i> , 2019, 18, 351-365.	0.7	13
164	A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules. <i>Statistics in Medicine</i> , 2020, 39, 3986-4000.	0.8	13
165	A Comparison of Procedures for Adaptive Choice of Location Tests in Flexible Two-Stage Designs. <i>Biometrical Journal</i> , 2003, 45, 292-310.	0.6	12
166	Sample Size Reassessment in Non-inferiority Trials. <i>Methods of Information in Medicine</i> , 2011, 50, 237-243.	0.7	12
167	Blinded sample size reestimation for recurrent event data with time trends. <i>Statistics in Medicine</i> , 2013, 32, 5448-5457.	0.8	12
168	Robustness of methods for blinded sample size reestimation with overdispersed count data. <i>Statistics in Medicine</i> , 2013, 32, 3623-3635.	0.8	12
169	Using phase II data for the analysis of phase III studies: An application in rare diseases. <i>Clinical Trials</i> , 2017, 14, 277-285.	0.7	12
170	Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events. <i>Pharmaceutical Statistics</i> , 2021, 20, 1125-1146.	0.7	12
171	Survival analysis for Adverse events with Varying follow-up times (SAVVY) estimation of adverse event risks. <i>Trials</i> , 2021, 22, 420.	0.7	12
172	Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3049.	1.0	12
173	Scientific Versus Experiential Evidence: Discourse Analysis of the Chronic Cerebrospinal Venous Insufficiency Debate in a Multiple Sclerosis Forum. <i>Journal of Medical Internet Research</i> , 2015, 17, e159.	2.1	12
174	RT-CMR Imaging for Noninvasive Characterization of HFpEF. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 943-945.	2.3	12
175	Study protocol: Improving patient choice in treating low back pain (IMPACT - LBP): A randomised controlled trial of a decision support package for use in physical therapy. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 52.	0.8	11
176	Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?. <i>PLoS ONE</i> , 2015, 10, e0116559.	1.1	11
177	Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0186387.	1.1	11
178	Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators. <i>Diabetes Care</i> , 2020, 43, 196-200.	4.3	11
179	Adaptive trial designs in diagnostic accuracy research. <i>Statistics in Medicine</i> , 2020, 39, 591-601.	0.8	11
180	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. <i>Acta Neuropathologica</i> , 2020, 139, 547-564.	3.9	11

#	ARTICLE	IF	CITATIONS
181	Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1558-1566.	2.8	11
182	Blinded and unblinded internal pilot study designs for clinical trials with count data. <i>Biometrical Journal</i> , 2013, 55, 617-633.	0.6	10
183	Decline of COPD exacerbations in clinical trials over two decades – a systematic review and meta-regression. <i>Respiratory Research</i> , 2019, 20, 186.	1.4	10
184	Prognostic significance of emergency department bypass in stable and unstable patients with ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 34-44.	0.4	10
185	Patient delay and benefit of timely reperfusion in ST-segment elevation myocardial infarction. <i>Open Heart</i> , 2021, 8, e001650.	0.9	10
186	T-wave loop area from a pre-implant 12-lead ECG is associated with appropriate ICD shocks. <i>PLoS ONE</i> , 2017, 12, e0173868.	1.1	10
187	A comparison of peritonitis in polycystic and non-polycystic patients on peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2004, 24, 79-81.	1.1	10
188	Considerations on what constitutes a “qualified statistician” in regulatory guidelines. <i>Statistics in Medicine</i> , 2012, 31, 1303-1305.	0.8	9
189	Cerebrospinal Fluid Apolipoprotein E Concentration and Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1229-1236.	1.2	9
190	Design and Development of a Decision Support Package for Low Back Pain. <i>Arthritis Care and Research</i> , 2014, 66, 925-933.	1.5	9
191	CR1 is potentially associated with rate of decline in sporadic Alzheimer's disease. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1705-1708.	0.8	9
192	Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data. <i>Biometrical Journal</i> , 2016, 58, 170-185.	0.6	9
193	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 16.	1.2	9
194	Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends. <i>Statistics in Medicine</i> , 2019, 38, 1503-1528.	0.8	9
195	Blinded continuous monitoring in clinical trials with recurrent event endpoints. <i>Pharmaceutical Statistics</i> , 2019, 18, 54-64.	0.7	9
196	Effects of strategies to improve general practitioner-nurse collaboration and communication in regard to hospital admissions of nursing home residents (interprof ACT): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2020, 21, 913.	0.7	9
197	Causal inference methods for small non-randomized studies: Methods and an application in COVID-19. <i>Contemporary Clinical Trials</i> , 2020, 99, 106213.	0.8	9
198	Peripheral Nerve Dysfunction in Middle-Aged Subjects Born with Thalidomide Embryopathy. <i>PLoS ONE</i> , 2016, 11, e0152902.	1.1	9

#	ARTICLE	IF	CITATIONS
199	Identifying back pain subgroups: developing and applying approaches using individual patient data collected within clinical trials. Programme Grants for Applied Research, 2016, 4, 1-278.	0.4	9
200	QRS micro-fragmentation as a mortality predictor. European Heart Journal, 2022, 43, 4177-4191.	1.0	9
201	Double arcsine transform not appropriate for meta-analysis. Research Synthesis Methods, 2022, 13, 645-648.	4.2	9
202	Intervention effects in observational survival studies with an application in total hip replacements. Statistics in Medicine, 2003, 22, 3725-3737.	0.8	8
203	Blinded assessment of treatment effects utilizing information about the randomization block length. Statistics in Medicine, 2009, 28, 1690-1706.	0.8	8
204	Blinded Sample Size Recalculation in Noninferiority Trials: A Case Study in Dermatology. Drug Information Journal, 2010, 44, 599-607.	0.5	8
205	Blinded sample size re-estimation in three-arm trials with "gold standard" design. Statistics in Medicine, 2017, 36, 3636-3653.	0.8	8
206	Group sequential designs for negative binomial outcomes. Statistical Methods in Medical Research, 2019, 28, 2326-2347.	0.7	8
207	Factors Influencing the Frequency of Airway Infections in Underage Refugees: A Retrospective, Cross Sectional Study. International Journal of Environmental Research and Public Health, 2020, 17, 6823.	1.2	8
208	A potential for seamless designs in diagnostic research could be identified. Journal of Clinical Epidemiology, 2021, 129, 51-59.	2.4	8
209	Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)" study protocol for a randomised controlled trial. Trials, 2021, 22, 139.	0.7	8
210	Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial. ESC Heart Failure, 2021, 8, 872-878.	1.4	8
211	Spline-based procedures for dose-finding studies with active control. Statistics in Medicine, 2015, 34, 232-248.	0.8	7
212	A systematic review identifies shortcomings in the reporting of crossover trials in chronic painful conditions. Journal of Clinical Epidemiology, 2015, 68, 1496-1503.	2.4	7
213	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine, 2018, 157, 163-177.	2.6	7
214	Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 173-174.	0.9	7
215	Modelling and sample size reestimation for longitudinal count data with incomplete follow up. Statistical Methods in Medical Research, 2019, 28, 117-133.	0.7	7
216	Data monitoring committees for clinical trials evaluating treatments of COVID-19. Contemporary Clinical Trials, 2020, 98, 106154.	0.8	7

#	ARTICLE	IF	CITATIONS
217	Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the <scp>EARLY PROTECT</scp> Alport trial. <i>Clinical Genetics</i> , 2021, 99, 143-156.	1.0	7
218	Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. <i>JACC: Heart Failure</i> , 2021, 9, 453-462.	1.9	7
219	Sample Size Adjustment in Clinical Trials for Proving Equivalence. <i>Drug Information Journal</i> , 2001, 35, 1401-1408.	0.5	6
220	A Note on Testing for Intervention Effects on Binary Responses. <i>Methods of Information in Medicine</i> , 2006, 45, 435-440.	0.7	6
221	P309 BLOOD PRESSURE PROFILE OF LUMIRACOXIB IS SIMILAR TO PLACEBO IN ARTHRITIS PATIENTS. <i>Osteoarthritis and Cartilage</i> , 2006, 14, S168-S169.	0.6	6
222	Software tools for implementing simulation studies in adaptive seamless designs: introducing R package ASD. <i>Trials</i> , 2011, 12, .	0.7	6
223	Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations. <i>Biometrical Journal</i> , 2017, 59, 344-357.	0.6	6
224	Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1462-1471.	1.4	6
225	A conditional error function approach for adaptive enrichment designs with continuous endpoints. <i>Statistics in Medicine</i> , 2019, 38, 3105-3122.	0.8	6
226	Strategies to reduce antibiotic use in women with uncomplicated urinary tract infection in primary care: protocol of a systematic review and meta-analysis including individual patient data. <i>BMJ Open</i> , 2020, 10, e035883.	0.8	6
227	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , 2021, 8, 26-36.	1.4	6
228	Bounds for the weight of external data in shrinkage estimation. <i>Biometrical Journal</i> , 2021, 63, 1131-1143.	0.6	6
229	Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 1885-1891.	1.4	6
230	Phase I dose-escalation oncology trials with sequential multiple schedules. <i>BMC Medical Research Methodology</i> , 2021, 21, 69.	1.4	6
231	Influence of individual, illness and environmental factors on place of death among people with neurodegenerative diseases: a retrospective, observational, comparative cohort study. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-003105.	0.8	6
232	Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events. <i>Biometrical Journal</i> , 2021, , .	0.6	6
233	Considerations in the design of clinical trials for relapsing multiple sclerosis. <i>Clinical Investigation</i> , 2012, 2, 1073-1083.	0.0	5
234	Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study. <i>Contemporary Clinical Trials Communications</i> , 2020, 18, 100574.	0.5	5

#	ARTICLE	IF	CITATIONS
235	Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data. <i>Biometrical Journal</i> , 2020, 62, 1284-1299.	0.6	5
236	Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study. <i>Europace</i> , 2022, 24, 774-783.	0.7	5
237	Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1). <i>BMJ Open</i> , 2021, 11, e041720.	0.8	5
238	Modeling the Recovery from Depressive Illness by an Exponential Model with Mixed Effects. <i>Methods of Information in Medicine</i> , 2000, 39, 12-15.	0.7	5
239	Managing neuropsychological impairment in multiple sclerosis – Controlled study on a standardized metacognitive intervention (MaTiMS). <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103687.	0.9	5
240	Anticholinergics for urinary symptoms in multiple sclerosis. <i>The Cochrane Library</i> , 2015, , CD004193.	1.5	4
241	Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer’s Disease. <i>Journal of Alzheimer’s Disease</i> , 2015, 48, 189-196.	1.2	4
242	The N-MOMentum trial: Building momentum to advance trial methodology in a rare disease. <i>Multiple Sclerosis Journal</i> , 2016, 22, 852-853.	1.4	4
243	Sample size re-estimation incorporating prior information on a nuisance parameter. <i>Pharmaceutical Statistics</i> , 2018, 17, 126-143.	0.7	4
244	Blinded continuous information monitoring of recurrent event endpoints with time trends in clinical trials. <i>Statistics in Medicine</i> , 2020, 39, 3968-3985.	0.8	4
245	Electrocardiogram as a predictor of survival without appropriate shocks in primary prophylactic ICD patients: A retrospective multi-center study. <i>International Journal of Cardiology</i> , 2020, 309, 78-83.	0.8	4
246	Noninferiority trials: What's clinically (ir)relevant?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 2119-2123.	0.4	4
247	Predicting menstrual bleeding patterns with levonorgestrel-releasing intrauterine systems. <i>European Journal of Contraception and Reproductive Health Care</i> , 2021, 26, 48-57.	0.6	4
248	Identification of subgroup effect with an individual participant data meta-analysis of randomised controlled trials of three different types of therapist-delivered care in low back pain. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 191.	0.8	4
249	A confidence interval robust to publication bias for random-effects meta-analysis of few studies. <i>Research Synthesis Methods</i> , 2021, 12, 674-679.	4.2	4
250	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	1.4	4
251	Work-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysis. <i>Journal of Occupational Medicine and Toxicology</i> , 2014, 9, 25.	0.9	3
252	Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 939-957.	0.4	3

#	ARTICLE	IF	CITATIONS
253	Contribution to the discussion of “When should meta-analysis avoid making hidden normality assumptions?”—A Bayesian perspective. <i>Biometrical Journal</i> , 2018, 60, 1068-1070.	0.6	3
254	Group sequential designs with robust semiparametric recurrent event models. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2385-2403.	0.7	3
255	Sporadic Creutzfeldt-Jakob Disease among Physicians, Germany, 1993–2018. <i>Emerging Infectious Diseases</i> , 2020, 26, .	2.0	3
256	Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study. <i>EClinicalMedicine</i> , 2021, 31, 100695.	3.2	3
257	Random-effects meta-analysis of Phase I dose-finding studies using stochastic process priors. <i>Annals of Applied Statistics</i> , 2021, 15, .	0.5	3
258	COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression. <i>ERJ Open Research</i> , 2022, 8, 00261-2021.	1.1	3
259	Classification of Companion Diagnostics: A New Framework for Biomarker-Driven Patient Selection. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 244-254.	0.8	3
260	Improving adaptive seamless designs through Bayesian optimization. <i>Biometrical Journal</i> , 2022, 64, 948-963.	0.6	3
261	A machine learning algorithm for electrocardiographic fQRS quantification validated on multi-center data. <i>Scientific Reports</i> , 2022, 12, 6783.	1.6	3
262	Plasma prion protein concentration and progression of Alzheimer disease. <i>Prion</i> , 2014, 8, 210-214.	0.9	2
263	Treatment for fatigue in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). <i>The Cochrane Library</i> , 2014, . .	1.5	2
264	An Unconditional Test for Change Point Detection in Binary Sequences with Applications to Clinical Registries. <i>Methods of Information in Medicine</i> , 2016, 55, 367-372.	0.7	2
265	Data on differential multivariable risk prediction of appropriate shock vs. competing mortality. <i>Data in Brief</i> , 2018, 21, 2110-2116.	0.5	2
266	A Dose Finding Design for Seizure Reduction in Neonates. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2019, 68, 427-444.	0.5	2
267	Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. <i>Annals of Oncology</i> , 2019, 30, iv129.	0.6	2
268	Semi-parametric analysis of overdispersed count and metric data with varying follow-up times: Asymptotic theory and small sample approximations. <i>Biometrical Journal</i> , 2019, 61, 616-629.	0.6	2
269	Repeating noninvasive risk stratification improves prediction of outcome in ICD patients. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12794.	0.5	2
270	Role of the proportion of sudden cardiac death to mortality for clinical effectiveness of primary prevention ICDs. <i>European Heart Journal</i> , 2020, 41, 4527-4528.	1.0	2

#	ARTICLE	IF	CITATIONS
271	Blinded sample size reestimation for negative binomial regression with baseline adjustment. <i>Statistics in Medicine</i> , 2020, 39, 1980-1998.	0.8	2
272	Using clinical trial registries to inform Copas selection model for publication bias in meta-analysis. <i>Research Synthesis Methods</i> , 2021, 12, 658-673.	4.2	2
273	Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression. <i>Journal of Neurology</i> , 2022, 269, 3226-3237.	1.8	2
274	24 Sketching behaviour in object recall and object copying. <i>Studies in Multidisciplinarity</i> , 2005, , 329-342.	0.0	1
275	Effect of the Left Internal Mammary Artery to the Left Anterior Descending Artery on Mortality and Morbidity After Combined Coronary and Valve Operations. <i>Annals of Thoracic Surgery</i> , 2005, 80, 163-169.	0.7	1
276	Comments on "Planning and analysis of three-arm non-inferiority trials with binary endpoints"™ by M. Kieser and T. Friede, <i>Statistics in Medicine</i> 2007; 26 :253-273. <i>Statistics in Medicine</i> , 2011, 30, 298-299.	0.8	1
277	Do we consent to rules of consent and confidentiality?. <i>Biometrical Journal</i> , 2017, 59, 235-239.	0.6	1
278	Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 44	0.4	1
279	First international meeting of early career investigators: Current opportunities, challenges and horizon in critical care nutrition research. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 92-100.	0.5	1
280	Exact change point detection with improved power in small sample binomial sequences. <i>Biometrical Journal</i> , 2021, 63, 558-574.	0.6	1
281	Sample Size Re-Estimation. , 2021, , 339-370.		1
282	Reduced <i>Clostridioides difficile</i> infections in hospitalised older people through multiple quality improvement strategies. <i>Age and Ageing</i> , 2021, 50, 2123-2132.	0.7	1
283	Subgroup identification in individual participant data meta-analysis using model-based recursive partitioning. <i>Advances in Data Analysis and Classification</i> , 2022, 16, 797-815.	0.9	1
284	Modeling the recovery from depressive illness by an exponential model with mixed effects. <i>Methods of Information in Medicine</i> , 2000, 39, 12-5.	0.7	1
285	Acute respiratory infections in an adult refugee population: an observational study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 50.	1.1	1
286	A straightforward meta-analysis approach for oncology phase I dose-finding studies. <i>Statistics in Medicine</i> , 2022, 41, 3915-3940.	0.8	1
287	Implementation, mechanisms of change and contextual factors of a complex intervention to improve interprofessional collaboration and the quality of medical care for nursing home residents: study protocol of the process evaluation of the interprof ACT intervention package. <i>Trials</i> , 2022, 23, .	0.7	1
288	Adaptive Design Methods in Clinical Trials by S. C. Chow and M. Chang. <i>Biometrics</i> , 2008, 64, 314-315.	0.8	0

#	ARTICLE	IF	CITATIONS
289	Statistics and Life Sciences 2008 – First Conference of the Central European Network of the International Biometric Society. <i>Biometrical Journal</i> , 2009, 51, 233-234.	0.6	0
290	FP36-WE-01 Adaptive seamless trial designs in neurology: a case study in secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009, 285, S113-S114.	0.3	0
291	Planning and analysis of three-arm non-inferiority trials with binary endpoints. <i>Statistics in Medicine</i> , 2011, 30, 300-300.	0.8	0
292	Calcineurin Inhibitor Sparing with Mycophenolate Mofetil in Liver Transplant Recipients: A Systematic Review and Meta-Analysis. <i>Transplantation</i> , 2012, 94, 745.	0.5	0
293	Quantitative approaches underpinning decision making. <i>Biometrical Journal</i> , 2019, 61, 1103-1103.	0.6	0
294	OC-0501 Chemo-RT plus induction or consolidation chemotherapy for rectal cancer: a randomised phase 2 trial. <i>Radiotherapy and Oncology</i> , 2019, 133, S257-S258.	0.3	0
295	Improved description of clinical features of multiple sulfatase deficiency: A meta-analysis of published cases. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S131.	0.5	0
296	Shrinkage Estimation for Dose-Response Modeling in Phase II Trials With Multiple Schedules. <i>Statistics in Biopharmaceutical Research</i> , 2020, , 1-13.	0.6	0
297	OC-0293 TNT in rectal cancer: Final results of the CAO/ARO/AIO-12 randomized phase 2 trial. <i>Radiotherapy and Oncology</i> , 2021, 161, S199-S200.	0.3	0
298	Efficiency of Adaptive Designs. , 2010, , 25-1-25-16.		0
299	Trials of Novel Therapies Specifically for Progressive MS. , 2018, , 233-252.		0
300	Clinical trial design: statistical issues. , 2018, , 3071-3077.		0
301	A note on testing for intervention effects on binary responses. <i>Methods of Information in Medicine</i> , 2006, 45, 435-40.	0.7	0
302	Sample size calculation for the augmented logrank test in randomized clinical trials. <i>Statistics in Medicine</i> , 2022, , .	0.8	0
303	Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642110704.	1.5	0
304	Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE) – a systematic review protocol. <i>Systematic Reviews</i> , 2022, 11, .	2.5	0